Table 3

Multivariate analysis of factors associated with infliximab discontinuation due to SLR or SAE

FactorORCI for ORP value
TDM never tested8.03.8 to 17.0<0.01
Pre-TDM era0.650.3 to 1.40.28
Previous exposure to biologic4.41.8 to 10.7<0.01
Total duration of follow-up1.010.99 to 1.020.07
  • SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.